5 completed, 2 recruiting, 1 active not recruiting. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Nodal Marginal Zone Lymphoma: new trials by email Literature Review of Nodal Marginal Zone Lymphoma trials Research Report on Nodal Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Ibrutinib, Rituximab - Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma | Phase 2 | Active not recruiting | International Extranodal Lymphoma Study Group (IELSG) | 175 | 2019-09-27 | 2026-04-08 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma Bortezomib, Rituximab, Cyclophosphamide - Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 2 | Completed | Mayo Clinic | 21 | 2008-08-01 | 2019-04-16 |
| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Laboratory Biomarker Analysis, Vorinostat - Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2005-09-01 | 2018-03-06 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Laboratory Biomarker Analysis, Tipifarnib - Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2004-03-24 | 2020-04-13 |
Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Non-Hodgkin (3) · Waldenstrom Macroglobulinemia (3) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Hairy Cell (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoma, B-Cell (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Lymphoma (7) · Lymphoma, Non-Hodgkin (5) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Leukemia (4) · Leukemia, B-Cell (4)
Rituximab (5) · ARQ531 (1) · Bendamustine Hydrochloride (1) · Biopsy (1) · Bortezomib (1) · CT-P10 (1) · Cyclophosphamide (1) · Dexamethasone (1) · Indium (1) · Magnetic Resonance Spectroscopy (1) · Photons (1) · ProMune (1) · Specimen Handling (1) · Vorinostat (1) · X-Rays (1)
National Cancer Institute (NCI) (3) · Mayo Clinic (2) · City of Hope Medical Center (1) · International Extranodal Lymphoma Study Group (IELSG) (1) · Izidore Lossos, MD (1)
United States (7) · Belgium (1) · France (1) · Italy (1) · Portugal (1) · Switzerland (1)
Annarita Conconi, MD (1) · Catherine Thieblemont, MD (1) · Craig Reeder (1) · Geoffrey Shouse (1) · Izidore Lossos, MD (1) · John Gerecitano (1) · Leslie Popplewell (1) · Thomas E Witzig (1) · Thomas Witzig (1)
PMID 40550489, PMID 21300924, PMID 21725056, PMID 28314788
P30CA015083 (3), P30CA033572 (2), 2018 (1), N01CM17101 (1), N01CM62209 (1), P30CA008748 (1), P50CA097274 (1), U01CA062505 (1), U01CA069856 (1)